Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sclerosing cholangitis in ulcerative colitis

E Schrumpf, K Elgjo, O Fausa

    Scandinavian Journal of Gastroenterology
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Lipid antigens in bile from patients with chronic liver diseases activate natural killer T cells.

    Clinical and experimental immunology·2020
    Same author

    Natural killer T cells mediate inflammation in the bile ducts.

    Mucosal immunology·2018
    Same author

    Secondary Osteoporosis in Liver Transplant Recipients: a Longitudinal Study in Patients With and Without Cholestatic Liver Disease.

    Scandinavian journal of gastroenterology·2017
    Same author

    Validation of a cholangiographic prognostic model in primary sclerosing cholangitis.

    Endoscopy·2010
    Same author

    Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis.

    Genes and immunity·2007
    Same author

    Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes.

    Tissue antigens·2007
    Same journal

    Assessing trial eligibility and real-world response to vedolizumab and ustekinumab in patients with ulcerative colitis.

    Scandinavian journal of gastroenterology·2026
    Same journal

    M2 macrophage activation in recurrent acute pancreatitis: an explorative analysis of a randomized controlled trial.

    Scandinavian journal of gastroenterology·2026
    Same journal

    Safety and performance of small bowel capsule endoscopy in patients with surgically altered gastrointestinal anatomy.

    Scandinavian journal of gastroenterology·2026
    Same journal

    Textbook outcome after esophagectomy in Norway - a national cohort study of low- to medium-volume centers.

    Scandinavian journal of gastroenterology·2026
    Same journal

    Fecal calprotectin concentration in adults with and without <i>Helicobacter pylori</i> infection.

    Scandinavian journal of gastroenterology·2026
    Same journal

    Endoloop-clip closure versus hemoclips for large sigmoid colon perforations: a randomized controlled <i>ex vivo</i> study.

    Scandinavian journal of gastroenterology·2026
    See all related articles

    Hepatobiliary disease affects 14% of ulcerative colitis patients. Sclerosing cholangitis was found in 4% of these patients, a higher incidence than previously estimated, often presenting asymptomatically.

    Area of Science:

    • Gastroenterology
    • Hepatology
    • Colorectal Surgery

    Background:

    • Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
    • Hepatobiliary complications can occur in patients with UC.
    • The incidence of sclerosing cholangitis in UC patients requires further investigation.

    Purpose of the Study:

    • To determine the incidence of hepatobiliary disease, specifically sclerosing cholangitis, in patients with ulcerative colitis.
    • To characterize the clinical presentation and diagnostic findings of hepatobiliary disease in UC patients.

    Main Methods:

    • A 5-year retrospective study of 336 ulcerative colitis patients.
    • Hepatobiliary disease was identified in 48 patients (14%).
    • Bile duct visualization and assessment for sclerosing cholangitis were performed in a subset of patients.

    Related Experiment Videos

    Main Results:

    • Sclerosing cholangitis was diagnosed in 14 patients (4% of all UC patients), a significantly higher rate than previously reported.
    • Patients with co-existing UC and hepatobiliary disease often had mild to moderate colitis, frequently affecting the entire colon.
    • The onset of colitis was typically before age 20 in this cohort.
    • Hepatobiliary disease was often asymptomatic.
    • Liver biopsy and biochemical data did not differentiate between patients with and without sclerosing cholangitis.

    Conclusions:

    • The incidence of sclerosing cholangitis in ulcerative colitis patients is higher than previously estimated.
    • Sclerosing cholangitis associated with ulcerative colitis may present asymptomatically and often occurs in patients with early-onset colitis.
    • Further longitudinal studies are needed to understand the natural history and management of sclerosing cholangitis in UC patients.